The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. has a group of affiliated Viking Global investment entities and individuals reporting passive ownership of its common stock on an amended Schedule 13G. Viking Global Investors LP and related entities, together with O. Andreas Halvorsen and Rose S. Shabet, report aggregate beneficial ownership of 1,503,478 shares of Oruka common stock.
The filing states this represents 2.5% of the 60,312,101 shares of common stock outstanding as of April 30, 2026, based on Oruka’s Form 10-Q. Of the reported holdings, 902,087 shares are directly owned by Viking Global Opportunities Illiquid Investments Sub-Master LP (VGOP) and 601,391 shares are directly owned by Viking Global Opportunities Drawdown (Aggregator) LP (VGOD). Voting and dispositive powers are shared across the Viking management entities, with no sole voting or dispositive power reported.
RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of Oruka Therapeutics, Inc. common stock. They collectively report 3,139,030 Shares of common stock, representing 5.2% of the class based on 60,312,101 Shares outstanding as of April 30, 2026.
All 3,139,030 Shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive power. The shares are directly held by funds advised by RTW Investments, and the RTW Funds have the right to receive dividends and sale proceeds. The filing clarifies it should not be construed as an admission of beneficial ownership for any Reporting Person.
Capital World Investors, a division of Capital Research and Management Company and its investment management affiliates, reports beneficial ownership of Oruka Therapeutics, Inc. common stock. The group is deemed to beneficially own 3,401,639 shares, representing 5.6% of Oruka’s 60,312,101 shares believed to be outstanding.
Capital World Investors holds sole voting power and sole dispositive power over all 3,401,639 shares, with no shared voting or dispositive power reported. The filing is signed by Timothy J. Moon, Vice President and Senior Counsel of Capital Research and Management Company.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapies for psoriasis and other inflammatory and immunology diseases. It reported a net loss of $41.2 million for the quarter and $73.0 million for the six months ended June 30, 2026, driven by rising research and development spending as multiple programs advance.
Quarterly research and development expense was $43.3 million, with general and administrative expense of $6.9 million. The company strengthened its balance sheet via an April 2026 underwritten offering raising $658.3 million net and ATM sales adding $38.9 million, boosting cash, cash equivalents and marketable securities to about $1.1 billion and total assets to $1.14 billion
Management expects these resources to fund operations for at least twelve months. Oruka’s lead IL‑23p19 antibody ORKA‑001 is in Phase 2a and 2b psoriasis trials, with Week 16 data from EVERLAST‑A showing 63.5% PASI 100 responders. IL‑17A/F antibody ORKA‑002 completed a Phase 1 trial and entered Phase 2 psoriasis and hidradenitis suppurativa studies, while TL1A antibody ORKA‑004 is planned to enter the clinic in late 2026.
Oruka Therapeutics, Inc. reported second quarter 2026 results and updated progress across its dermatology pipeline. The company is advancing ORKA-001, a half-life extended IL-23p19 monoclonal antibody, and ORKA-002, a half-life extended IL-17A/F monoclonal antibody, with multiple clinical data readouts planned through 2026 and into 2027. EVERLAST-A Week 28 data are expected at the end of the third quarter of 2026, with 52-week data for all participants anticipated in December 2026, while EVERLAST-B is fully enrolled ahead of schedule with Week 16 data expected in the fourth quarter of 2026. ORCA-SURGE Week 16 data are now expected in the first quarter of 2027, ORCA-SPLASH, a Phase 2 trial of ORKA-002 in hidradenitis suppurativa, has been initiated, and ORKA-004 is expected to enter the clinic in the fourth quarter of 2026.
As of June 30, 2026, Oruka held $1.1 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations through an anticipated BLA filing for ORKA-001 and continued development of ORKA-002. Second quarter 2026 research and development expenses were $43.3 million versus $24.1 million a year earlier, and general and administrative expenses were $6.9 million versus $4.3 million. Other income, net, was $8.9 million, primarily from interest on higher cash and marketable securities. Net loss for the quarter was $41.2 million compared with $24.6 million in the prior-year quarter, reflecting increased investment in clinical programs and corporate infrastructure.
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves reported same-day option exercises and stock sales on July 15, 2026. She exercised awards for 7,000 common shares at strike prices of $6.84 and $7.80, then sold 7,000 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan, with weighted-average sale prices in ranges spanning $83.87 to $87.26 per share.
Orka shareholder Joana Goncalves plans to sell 21,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with a proposed sale date of 07/15/2026 and an aggregate market value of $1,836,870.00. The shares are listed as acquired via exercise of stock options for cash.
Recent activity includes three 10b5-1 sales of Orka common stock: 7,000 shares on 06/15/2026 for $484,610.70, 947 shares on 06/15/2026 for $65,996.43, and 7,000 shares on 05/15/2026 for $432,935.30.
Oruka Therapeutics, Inc. Senior Vice President, Finance Agarwal Arjun reported open-market sales of common stock and exercises of employee stock options on July 13, 2026. He sold a total of 9,999 shares of common stock in multiple open-market transactions at weighted-average prices between $82.49 and $85.69 per share, pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. On the same date, he exercised employee stock options to acquire 9,999 shares of common stock at exercise prices of $34.39 and $12.50 per share.
ORKA has a notice of proposed sale under Form 144 for 28,588 common shares, to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are planned to be sold on July 13, 2026 in connection with an exercise of stock options for cash.
The filing also lists recent Rule 10b5-1 sales by Arjun Agarwal over the prior three months, including multiple transactions in May and June 2026 involving several thousand shares each.
ORKA notice of proposed sale: 3,553,410 shares of Common Stock are tied to the conversion of Series B Non-Voting Convertible Preferred Stock, dated 07/01/2026. The filing lists Goldman Sachs & Co. LLC as the broker/dealer associated with the transaction.